Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease

Long-term safety of brazikumab in the open-label period of a randomized phase 2a study of patients with Crohn’s disease

Abstract Background Short-term efficacy and safety of brazikumab (MEDI2070), a human monoclonal antibody and anti-p19 subunit inhibitor of interleukin-23, was demonstrated in a phase 2a trial in patients with moderate-to-severe active Crohn’s disease (CD). We report brazikumab long-term safety and t...

Full description

Bibliographic Details
Main Authors: Silvio Danese, Andrew Beaton, Elizabeth A. Duncan, Anne-Kristina Mercier, Jessica Neisen, Henrik Seth, Sofia Zetterstrand, Bruce E. Sands
Format: Article
Language:English
Published: BMC 2023-12-01
Series:BMC Gastroenterology
Subjects:
Biologics
Crohn’s disease
Inflammatory bowel disease
Online Access:https://doi.org/10.1186/s12876-023-03078-7

Internet

https://doi.org/10.1186/s12876-023-03078-7

Similar Items